|Bid||0.0000 x 1000|
|Ask||0.0000 x 800|
|Day's Range||2.3700 - 2.6400|
|52 Week Range||1.1900 - 12.9900|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors need to pay close attention to Galera (GRTX) stock based on the movements in the options market lately.
An "error" in previously released results sent the company's stock price down by more than 70% in October.
Galera Therapeutics (NASDAQ:GRTX) stock is rocketing higher on Tuesday after the cancer treatment company revealed corrected results from a Phase 3 clinical trial. Source: Bukhta Yurii / Shutterstock.com According to a press release from the company, its Phase 3 ROMAN study covering the treatment of “RT-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC)” with avasopasem did better than expected. Galera Therapeutics says this has avasopasem reaching i